Medical Access in Iraq

Currently classified as a strictly controlled substance under Iraq’s Narcotic Drugs and Psychotropic Substances Law No. 50 of 2017, with no authorized medical use outside of approved clinical research or explicit regulatory exception. The 2017 law and subsequent anti‑narcotics enforcement prioritize criminalization and interdiction of psychotropic substances; there is no national reimbursement pathway or licensed medical program for psilocybin therapy in Iraq. [1]Iraqi Law No.50 analysis [2]UN Treaty accession record.

Currently classified as a strictly controlled substance under Iraq’s narcotics and psychotropic substances law, with no authorized medical use or reimbursement outside of approved clinical research. National policy and enforcement (Interior Ministry anti‑narcotics directorates and the High Committee for Combating Narcotic and Psychotropic Substances) treat MDMA as an illicit psychotropic; there is no recognized MDMA‑assisted therapy program or public/private insurance coverage in Iraq. [1]Iraqi Law No.50 analysis [2]KRG/anti‑narcotics activity.

Esketamine (the intranasal product marketed in some jurisdictions for treatment‑resistant depression) does not appear to have an established, licensed and reimbursed regulatory pathway in Iraq. There is no public evidence of a national approval/registration and reimbursement program for esketamine through the Iraqi Ministry of Health’s registration/importation lists, and Iraqi psychiatric practice has not published national guidance adopting esketamine as a reimbursed treatment. Clinically available anesthetic/analgesic agents in Iraq are managed via standard MOH procurement and hospital formularies, but novel psychiatric agents requiring specialist licensing and pharmacovigilance (like esketamine) require explicit registration and guidance that is not publicly documented for Iraq. For example, the Iraqi MOH maintains a national drug list/registration process for approved medical products but esketamine is not documented in available public MOH product lists or clinical reports. [1]Iraq MOH national drug list portal [2]Iraqi Law No.50 analysis.

Ketamine is an established and routinely used anesthetic and analgesic in Iraqi clinical practice (public and private hospitals) and is available through standard medical procurement/registration channels rather than as a recreationally tolerated substance. Multiple Iraq‑based clinical reports and trial registrations document ketamine use for anesthesia and perioperative analgesia (e.g., published hospital studies and a clinical trial record listing the Iraqi Ministry of Health as a contact site), supporting that ketamine is part of routine medical care in Iraq. Public reimbursement varies by setting: inpatient anesthesia and emergency use of registered anesthetics (including ketamine) are provided through hospital budgets and MOH supply chains in public hospitals, while private hospitals procure via normal import/registration processes; there is no evidence of a dedicated national reimbursement policy that specifically covers ketamine for off‑label psychiatric indications (e.g., repeated IV ketamine for depression) as a covered mental‑health treatment. Providers using ketamine for anesthesia operate under MOH hospital formularies and procurement. [1]Iraq clinical trial record showing Ministry of Health site with ketamine in anesthesia protocols [2]Iraq MOH national drug list portal.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Iraq’s anti‑narcotics legal framework criminalizes psychotropic tryptamines and there is no established medical or reimbursement pathway for DMT. [1]Iraqi Law No.50 analysis [2]UN Treaty accession record.

Currently classified as a strictly controlled substance under Iraq’s narcotics and psychotropic substances law, with no authorized medical use or reimbursement outside of approved clinical research. There is no public regulatory pathway for clinical use of 5‑MeO‑DMT in Iraq. [1]Iraqi Law No.50 analysis.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Iraq’s legislation and enforcement focus on psychotropic and narcotic control; ibogaine‑based treatment centers and reimbursement frameworks are not available in Iraq. [1]Iraqi Law No.50 analysis.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Preparations containing DMT (the principal psychoactive component of ayahuasca brews) fall under prohibitions in Iraq’s psychotropic substances controls; there is no legal medical/ceremonial or reimbursed pathway. [1]Iraqi Law No.50 analysis.

Currently classified as a strictly controlled substance under Iraq’s narcotics/psychotropic legislation, with no authorized medical use outside of approved clinical research. Mescaline and mescaline‑containing extracts are treated as illicit psychotropic substances under the national control framework; no medical reimbursement or legal therapeutic program exists for mescaline in Iraq. [1]Iraqi Law No.50 analysis.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The 2C family and related phenethylamine psychedelics are encompassed by Iraq’s psychotropic substance controls and law enforcement actions; there is no medical/reimbursed access. [1]Iraqi Law No.50 analysis.